Academic and patient advocacy group collaborations in Dentatorubral-pallidoluysian atrophy (DRPLA)

Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare progressive brain disorder that can impact children and adults. In children, DRPLA can lead to difficulties walking, talking, eating, epilepsy, and progressive intellectual deterioration. In adults, it manifests as movement impairment, talking and eating difficulties, and dementia or behavior changes. 

Redenlab are supporting communication testing and analysis in two multi-domain assessment studies. One, collaborating with Boston Children’s Hospital, Harvard University and The University of Melbourne to measure novel treatment outcomes. The second is a multi-national natural history study across North America and Europe run by CureDRPLA and Ataxia UK.

Related Post

  • Posted on 14 September, 2023
    Redenlab, a leading provider of innovative solutions in the field of pediatric and neurodevelopment communication, proudly announces that Professor Angela...
    • Posted on 27 April, 2023
      MEDIA RELEASERedenlab, a leading techbio company, proudly announces its recent feature on the highly acclaimed Huberman Podcast. The podcast episode...
      • Posted on 30 March, 2023
        L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays in children...